The landscape of modern medicine is increasingly shaped by biologics, with therapeutic antibodies playing a pivotal role in treating a wide range of severe diseases, from autoimmune disorders to cancer. The journey from a discovery-stage molecule to a safe and effective drug is a complex and resource-intensive process. A critical first step in this pipeline is the identification of potent and selective antibodies that exhibit favorable drug-like properties. However, a significant challenge in therapeutic antibody discovery is the high attrition rate of promising candidates due to liabilities that emerge late in development, such as poor stability, aggregation, or immunogenicity.
This challenge has driven biopharmaceutical companies to seek more reliable and efficient methods for discovering and developing antibodies. One powerful approach is the use of in vitro display technologies, such as phage display, which enable the screening of vast libraries of antibodies against a target of interest. The quality of the antibody library—the diversity, stability, and human-like nature of the antibodies it contains—is paramount to the success of this approach. It is within this context that Specifica, a leader in antibody library platforms, has partnered with UCB, a global biopharmaceutical company dedicated to developing innovative medicines for severe immunological and central nervous system diseases.
UCB and Specifica partner to advance antibody drug discovery
In a significant move to strengthen its drug development pipeline, UCB has acquired an exclusive license to Specifica's Generation 3 Library Platform. This partnership is designed to provide UCB's scientists with a new, powerful tool to complement their existing technologies, including a powerful immunization-based single B cell screening platform.
Daniel Lightwood, UCB’s head of Antibody Discovery, explained the rationale behind the acquisition, stating, “The Specifica Generation 3 Library provides a new tool to use alongside our existing platforms and technologies, which enhances our therapeutic antibody discovery capabilities. We expect that the platform will provide a more reliable and rapid source of therapeutic antibody molecules than previous in-vitro display technologies, and it complements our existing powerful immunization-based single B cell screening platform.”
This strategic investment underscores UCB’s commitment to staying at the forefront of antibody drug discovery by utilizing a platform that has been rigorously vetted for its potential to yield molecules with desirable properties and forms. According to Kenneth Sharples, CEO and co-founder of Specifica, the platform's value lies in its “quality built-in by design.” He further noted that “Antibodies from our Generation 3 Platform have few liabilities, and over 80 percent behave as well as—or better than—the best therapeutic antibodies. We’re pleased to arm UCB with a high-quality discovery platform and the training and support to ensure its value to drug discovery for years to come.”
Key features of the Specifica Generation 3 library pPlatform
The Specifica Generation 3 Library Platform is a testament to the latest advancements in antibody engineering. The platform's high-quality antibodies are the result of meticulous design and validation processes. Each library provided to a partner is created from unique donor sets, ensuring that it is one of a kind and exclusive to that partner, providing a competitive advantage in the drug discovery landscape.
A Tale of Two Formats: Fab vs. scFv
Specifica's library platforms are available in two primary formats, each with distinct characteristics and applications in therapeutic antibody discovery:
Format | Description | Advantages |
|---|
Fab (Fragment, antigen-binding) | A fragment of an antibody that includes one variable region and its associated constant region. | More closely mimics a full-length IgG molecule, often leading to better expression and stability. The structure is well-understood and can reduce late-stage development liabilities. |
scFv (Single-chain variable fragment) | A single polypeptide chain that contains both the variable heavy (VH) and light (VL) regions of an antibody, connected by a flexible linker. | A smaller construct that is easier to clone and express in various systems. Its single-gene nature simplifies genetic manipulation and library construction. |
The choice between the Fab and scFv formats depends on the specific discovery and development goals. While the scFv format's single-gene simplicity makes it easier to work with for initial screening, the Fab format’s closer resemblance to the final IgG molecule can provide a more accurate representation of the molecule's behavior from the outset, potentially streamlining downstream development.
Next-generation sequencing for quality control
A key technological differentiator for the Specifica platform is the rigorous use of next-generation sequencing (NGS) for quality control. NGS allows for the high-throughput sequencing of millions of DNA fragments in parallel. By applying this method at every step of library construction and validation, Specifica can ensure a high standard of diversity. This process allows them to accurately count the number of different antibodies within a library, guaranteeing that the platform provides a truly diverse and unique starting point for any drug discovery program. This level of comprehensive quality control is critical for building a robust and reliable discovery platform that can consistently yield high-quality leads.
The future of therapeutic antibody discovery
The partnership between Specifica and UCB marks a significant step forward in the field of therapeutic antibody discovery. By integrating Specifica’s pre-validated, high-quality library platform into its existing capabilities, UCB aims to accelerate the discovery process and increase the probability of success for its antibody drug candidates. The platform’s ability to provide a "more reliable and rapid source of therapeutic antibody molecules" addresses a long-standing need in the biopharmaceutical industry.
As the industry continues to advance, the focus will increasingly shift from simply finding a molecule that binds to a target to finding a molecule that is also "developable"—one that can be successfully manufactured, formulated, and administered with minimal risk of liabilities. The Specifica Generation 3 Library, with its built-in quality and exclusive nature, is well-positioned to help UCB and other partners meet this demand and drive the next wave of innovation in antibody-based medicines.
Frequently asked questions about antibody discovery
What is the Specifica Generation 3 Library Platform and how does it help UCB?
The Specifica Generation 3 Library Platform is a high-quality antibody library that provides UCB with a new, exclusive tool for therapeutic antibody discovery. Its unique design, which builds in quality and minimizes liabilities from the outset, is expected to provide a more reliable and rapid source of drug-like antibody candidates for UCB's pipeline.
What technologies make the Specifica antibody library platform unique?
A key differentiator is the use of next-generation sequencing (NGS) throughout the entire process of library construction and validation. This advanced technology allows Specifica to precisely count the number of different antibodies in each library, ensuring high diversity and a robust starting point for any drug discovery program.
What is the difference between Fab and scFv formats in antibody discovery?
Specifica's libraries come in both Fab and scFv formats, each with distinct applications. The Fab format more closely resembles a full-length antibody, which can lead to better stability and fewer liabilities later in development. The scFv is a simpler, single-gene construct that is often easier to use for initial cloning and expression.
